Inmune Bio Inc.

INMB Nasdaq SEC CIK 1711754
Follow Inmune Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$4.7M +27% vs same quarter last year
EPS, diluted −$0.17 +29.2% vs same quarter last year
Operating cash flow −$3.4M +37.7% vs same quarter last year
Operating income −$5M +32.6% vs same quarter last year
Revenue by quarter
$0
$50K
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$50K−$46M
FY24$14K−$42M
FY23$155K−$30M
FY22$374K−$27.3M
FY21$181K−$30.3M
FY20$11K−$12.1M
FY19-−$7.7M
FY18$0−$12.4M
FY17$0−$831.5K
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400000%−300000%−200000%−100000%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−94766%−92000%
FY24−304535.7%−300000%
FY23−19187.7%−19354.8%
FY22−6938.8%−7299.2%
FY21−16106.6%−16762.4%
FY20−111163.6%−109990.9%
FY19--
FY18--
FY17--
FY16--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Inmune Bio
  • Healthcare median
−300000%−200000%−100000%0%FY17FY19FY21FY23FY25
Show the numbers
YearInmune BioHealthcare median
FY25−92000%−30.6%
FY24−300000%−47%
FY23−19354.8%−58%
FY22−7299.2%−80.4%
FY21−16762.4%−71.8%
FY20−109990.9%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%